Nasal administration

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

Retrieved on: 
Thursday, November 3, 2022

FORT WORTH, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced a collaboration with Aptar Pharma, a global leader in drug delivery and active material science solutions and services, aimed at developing and testing the administration of dry powder vaccines utilizing TFF Pharmaceutical’s Thin Film Freezing technology and Aptar Pharma’s proprietary intranasal Unidose (UDS) Powder Nasal Spray System.

Key Points: 
  • The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery.
  • These aspects of nasal delivery could expand vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
  • During the Vaccines Summit-2022, which took place from October 11 to 13, 2022 in Washington DC, U.S., Aptar Pharma presented research findings from their collaboration with TFF Pharmaceuticals.
  • Intranasal dry powder vaccines could be a true game changer for people around the world.

Homewood Health introduces its Interventional Psychiatry Service (IPS)

Retrieved on: 
Wednesday, October 19, 2022

GUELPH, ON, Oct. 19, 2022 /CNW/ - Homewood Health announces the launch of its Interventional Psychiatry Service (IPS), featuring cutting-edge treatment options for individuals suffering from treatment-resistant depression and other mental health conditions.

Key Points: 
  • GUELPH, ON, Oct. 19, 2022 /CNW/ - Homewood Health announces the launch of its Interventional Psychiatry Service (IPS), featuring cutting-edge treatment options for individuals suffering from treatment-resistant depression and other mental health conditions.
  • Interventional Psychiatry is an emerging subspecialty within Psychiatry that encompasses various neuromodulation treatments such as Electroconvulsive Therapy (ECT) and Repetitive Transcranial Magnetic Stimulation (rTMS), as well as novel psychopharmacological agents such as ketamine.
  • Homewood's IPS delivers on its pledge to consistently provide innovative approaches to mental health and addiction treatment, combining evidence-based treatments, measurement-based care, and Homewood's deep expertise in mental health.
  • Homewood Health is a Canadian leader in the development and delivery of national, evidence-based mental health, trauma, and addiction treatment and services since 1883.

Elicio Therapeutics Announces Publication of Preclinical Data in Science Translational Medicine Demonstrating the AMP Platform Promotes Uptake of Intranasal Vaccine in the Mucosa Amplifying Immune Response

Retrieved on: 
Tuesday, October 4, 2022

BOSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the publication of preclinical data from the research laboratory of Dr. Darrell Irvine at the Massachusetts Institute of Technology (MIT), demonstrating Elicio’s Amphiphile (AMP) platform conjugated to protein antigens promotes uptake in the nasal mucosa and amplifies immune responses after intranasal immunization. Immunization through airway surfaces has proven challenging due to poor vaccine uptake across these linings. The data presented here represents a promising strategy to promote mucosal immunity against HIV, SARS-CoV-2, and other infectious diseases. The data was published in Science Translational Medicine and can be accessed here.

Key Points: 
  • The data was published in Science Translational Medicine and can be accessed here .
  • Delivery of vaccine components across mucosal barriers has been a major challenge for mucosal vaccine development.
  • This data demonstrates that AMP-modification can improve vaccine uptake across the nasal mucosa via interactions with albumin and the neonatal Fc receptor known as the mucosal gateway.
  • The findings are encouraging for the translational potential of this approach to induce antibodies in a variety of mucosal sites after intranasal immunization.

Hepatitis Drugs Global Market Report 2022: Featuring Gilead, F Hoffmann-La Roche, Johnson & Johnson, Merck & GlaxoSmithKline PLC - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022

The "Hepatitis Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatitis Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increasing number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drugs market.
  • Various types of hepatitis need different drugs for treatment and this increases the demand for hepatitis drugs.

Global Non-steroidal Anti-inflammatory Drugs Market Report 2022: Rising Prevalence of Targeted Diseases and Chronic Pain Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 15, 2022

The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period.

Key Points: 
  • The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period.
  • Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature.
  • The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population.
  • Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period.

Insights on the Nasal Drug Delivery Mode Global Market to 2028 - Size, Share, Outlook and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 1, 2022

Drug delivery refers to the technology utilized to present the drug to the desired body site for drug release and absorption.

Key Points: 
  • Drug delivery refers to the technology utilized to present the drug to the desired body site for drug release and absorption.
  • The global nasal drug delivery mode market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal drug delivery mode market.
  • Global Nasal Drug Delivery Mode Market, By Therapeutic Application:

Intranasal Drug Delivery Global Market Report 2022: Rise in Prevalence of COPD Drives Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022

The "Intranasal Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intranasal Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Nasal drug delivery route is suitable for systematic drug delivery, needleless vaccination, and for drug candidates with low oral absorption or vulnerable to first-pass effect in the human body.
  • This segment currently accounts for a 31.5% share of the global Intranasal Drug Delivery market.
  • North America represents the leading global market for intranasal drug delivery, driven by the growing prevalence of respiratory disorders, such as asthma and COPD; the high adoption of drug delivery technique in healthcare institutions; and the growing affinity of patients for affordable generic drugs.

Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines

Retrieved on: 
Wednesday, July 27, 2022

Meissa Vaccines (Meissa), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced that Martin Moore, Ph.D., cofounder and Chief Scientific Officer of Meissa, spoke on a panel entitled, Innovation in Vaccine Delivery, at the Summit on the Future of COVID-19 Vaccines hosted by The White House Office for COVID-19 Response.

Key Points: 
  • Meissa Vaccines (Meissa), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced that Martin Moore, Ph.D., cofounder and Chief Scientific Officer of Meissa, spoke on a panel entitled, Innovation in Vaccine Delivery, at the Summit on the Future of COVID-19 Vaccines hosted by The White House Office for COVID-19 Response.
  • Meissas MV-014-212, the companys intranasal recombinant live attenuated COVID-19 vaccine, is currently in a Phase 1 study in adults (ClinicalTrials.gov Identifier: NCT04798001 ).
  • Injectable vaccines typically induce only serum (IgG) antibodies that circulate in the blood and are important for preventing serious lung disease.
  • Meissa is advancing live attenuated vaccine candidates against respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV).

Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

Retrieved on: 
Monday, July 11, 2022

Meissa Vaccines (Meissa), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development.

Key Points: 
  • Meissa Vaccines (Meissa), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development.
  • Martin Moore, Ph.D., cofounder of Meissa, will serve as the Companys Chief Scientific Officer.
  • I am excited to welcome Frank to the Meissa leadership team, said Dr. Moore.
  • I look forward to continuing to work with Frank and the Meissa team to drive our platform and vaccine candidates forward.

Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

Retrieved on: 
Thursday, June 9, 2022

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second secondary progressive multiple sclerosis (SMPM) patient in a June 8th press release. The ~40 year old individual that was enrolled as the second patient in the trial exhibited clinical improvements on several measures, including positron emission tomography (PET) analysis, neurologic exam and the timed 25-foot walk test after three months of treatment. The results from the second patient are consistent with the results from the first patient which were reported in a March 10 press release. Based on the data gathered from the first two subjects, Tiziana has requested and the FDA has cleared enrollment of eight more eligible SMPS patients to receive intranasal foralumab, a fully human anti-CD3 monoclonal antibody therapy, under the Expanded Access Program.

Key Points: 
  • The second patient was diagnosed with SPMS in 2014 and over the subsequent eight years, the magnitude of his disability increased.
  • See link here for the discussion on the results for the first patient and detailed background on SPMS.
  • In the clinical sphere, investigators observed improvements in the 25-foot walk test and the neurologic exam for patient #2.
  • Intranasal Foralumabs First SPMS Patient: 3- and 6-Month Data, KOL Discussion
    On January 10, 2022, Tiziana provided a progress update for its first patient in the evaluation of intranasal foralumab in SPMS.